Free press releases distribution network?

Agency / Source: Attana AB

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development - Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body
Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development

 

PRZOOM - /newswire/ - Stockholm, Sweden, 2010/02/01 - Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

As the first company in the world, Attana launches a system measuring molecular interactions label free directly on cell surfaces. In line with Attana’s innovative strategy, the Attana Cell 200 is a revolutionary system that rapidly generates biologically relevant information on molecular interactions with cell surfaces. Thanks to groundbreaking innovations and sedulous developments, Attana is the only player on the market that offers cells integrated as sensor surface. The experiments mimic real life conditions and generate information with higher biological relevance in comparison with traditional synthetic sensor surfaces.

Drug development is financially risky and time consuming. To save money and time the industry needs to early identify and eliminate unsuitable candidates. Attana Cell 200 biosensor system improves the selection process by rapidly identifying promising drug candidates. This enables early and well informed decisions in selecting relevant candidates while reducing unnecessary development costs and saving time. The Attana Cell 200 is label free, can run unpurified candidate molecules and has high throughput, resulting in fast and efficient screening of many drug candidates.

Attana Cell 200 is launched with new applications such as kinetic evaluation of cellular biomolecular interactions, e.g. antibody-receptor and lectin-carbohydrate, competition assays and cell capturing.

About Attana AB

Based in Stockholm, Sweden, Attana AB (attana.com) develops and sells biosensors for analysis of biomolecular interactions. Our systems have since 2003 been employed at leading life science companies and universities worldwide, working in a wide variety of research fields. Attana’s biosensors can be used to determine specificity, kinetics and affinity, amongst other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Attana AB

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Attana AB Introduces the Attana Cell 200 - Potentially Improves Drug Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Gabriela Suhoschi - Attana.com 
+46(0)8 674 57 12 gabriela.suhoschi[.]attana.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Attana AB securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Attana AB / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com

Visit  MagLar, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today